Jasper Therapeutics announced it has appointed Lawrence Klein and Chris Nolet to its board of directors, where they’ll help guide the development of the company’s anti-CD117 monoclonal antibody and stem cell platform. Klein serves as COO at CRISPR Therapeutics, and Nolet brings experience as an audit partner and business advisor in life sciences.

“We are pleased to appoint Lawrence and Chris to the Jasper board of directors to add additional expertise to the team in cellular and gene therapy development and to build a leading public biotechnology company,” Bill Lis, executive chairman and CEO at Jasper, said in a statement.